Match!
Thomas Dörner
Charité
Physical therapyImmunologyLupus erythematosusB cellMedicine
296Publications
57H-index
12.1kCitations
What is this?
Publications 305
Newest
#1Arman Aue (Charité)
#2Franziska Szelinski (Charité)H-Index: 2
Last. Thomas Dörner (Charité)H-Index: 57
view all 7 authors...
OBJECTIVES: SLE is characterized by two pathogenic key signatures, type I IFN and B-cell abnormalities. How these signatures are interrelated is not known. Type I-II IFN trigger activation of Janus kinase (JAK) - signal transducer and activator of transcription (STAT). JAK-STAT inhibition is an attractive therapeutic possibility for SLE. We assess STAT1 and STAT3 expression and phosphorylation at baseline and after IFN type I and II stimulation in B-cell subpopulations of SLE patients compared w...
Source
#1Marie Lettau (Charité)H-Index: 1
#2Eva Schrezenmeier (Charité)H-Index: 5
Last. Thomas Dörner (Charité)H-Index: 57
view all 4 authors...
Even early on thromboembolic events were observed in patients with systemic lupus erythematosus (SLE) until the antiphospholipid syndrome (APS) was described in the 1980s as an independent disorder. The APS is a systemic autoimmune disease often overlapping with SLE in which antiphospholipid autoantibodies, including lupus anticoagulant, can cause a hypercoagulation state, which clinically by definition is manifested as arterial and venous occlusions or pregnancy complications. The pathophysiolo...
Source
#1Rieke Alten (Charité)H-Index: 42
#2M. Mischkewitz (Charité)
Last. Thomas Dörner (Charité)H-Index: 57
view all 4 authors...
BACKGROUND: Cytokines and associated intracellular signal cascades play a major role in the pathogenesis of autoimmune diseases. Janus kinases (JAK) are part of these intracellular signal transduction processes. A relatively new drug group of targeted synthetic disease-modifying antirheumatic drugs (tsDMARD) are JAK inhibitors (JAKi) and are a promising treatment approach for autoimmune diseases. EFFICACY: Hitherto, three JAKis, Tofacitinib, Baricitinib and Upadacitinib, have been approved for t...
Source
#1Jonathan Kay (UMMS: University of Massachusetts Medical School)H-Index: 41
#2Thomas Dörner (Charité)H-Index: 57
Last. Ferdinand C. Breedveld (LUMC: Leiden University Medical Center)H-Index: 61
view all 5 authors...
In their correspondence, Cantini and Benucci1 voice concern regarding the recommendation of our international multidisciplinary task force on biosimilars that ‘a single switch from a bio-originator to one of its biosimilars is safe and effective.’2 This recommendation was based on consistent evidence from randomised controlled trials comparing biosimilars to their respective reference products in patients with rheumatologic diseases, in which subjects treated with a reference product were subseq...
2 CitationsSource
#1Martin Aringer (TUD: Dresden University of Technology)H-Index: 47
#2Nicolai Leuchten (TUD: Dresden University of Technology)H-Index: 6
Last. Thomas Dörner (Charité)H-Index: 57
view all 3 authors...
Targeted treatment is a rheumatologist's dream, which, with the advent of biologicals and more recently small molecules, has become true for rheumatoid arthritis and is about to translate into reality for systemic lupus erythematosus (SLE). Belimumab, the first biological approved for SLE, is now also available in a subcutaneous formulation. It is notable that this drug achieved the primary endpoint in four independent trials and demonstrated substantial reduction of organ damage accrual. The B ...
Source
#1Marie Lettau (Charité)H-Index: 1
#2Annika Wiedemann (Charité)H-Index: 3
Last. Thomas Dörner (Charité)H-Index: 57
view all 5 authors...
BACKGROUND: Memory B cell (mBC) induction and maintenance is one of the keys to long-term protective humoral immunity. MBCs are fundamental to successful medical interventions such as vaccinations and therapy in autoimmunity. However, their lifestyle and anatomic residence remain enigmatic in humans. Extrapolation from animal studies serves as a conceptual basis but might be misleading due to major anatomical distinctions between species. METHODS AND FINDINGS: Multicolor immunofluorescence stain...
Source
#1Christof SpeckerH-Index: 22
Last. Thomas Dörner (Charité)H-Index: 57
view all 3 authors...
Antiphospholipid syndrome (APS) was first identified in patients with systemic lupus erythematosus (SLE) and frequent occurrence of thromboembolic complications and miscarriages accompanied by detection of anticardiolipin antibodies (aCL). When APS was also later found without an underlying SLE, the so-called primary APS was distinguished from its secondary form with SLE. Even more specific than aCL are the lupus anticoagulant (LA) and antibodies against beta2 glycoprotein I (aB2GP I). In recent...
Source
Despite widespread clinical use of antimalarial drugs such as hydroxychloroquine and chloroquine in the treatment of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and other inflammatory rheumatic diseases, insights into the mechanism of action of these drugs are still emerging. Hydroxychloroquine and chloroquine are weak bases and have a characteristic ‘deep’ volume of distribution and a half-life of around 50 days. These drugs interfere with lysosomal activity and autophagy, int...
46 CitationsSource
Recent advances in rheumatology indicate increased relevance of autoantibodies. In this regard, positive ANA are now required as entrance criterium for the first EULAR/ACR classification criteria of SLE. Importantly, ANA diagnostic with detection of isolated anti-dense fine speckled antibodies (DSF-70) need consideration since their unique detection has been identified to exclude largely an autoimmune disease. Thus, highly qualified ANA diagnostic preferably on Hep-2 cell lines is a prerequisite...
Source
#1Eva Schrezenmeier (Charité)H-Index: 5
#2Andreia C. LinoH-Index: 2
Last. Thomas Dörner (Charité)H-Index: 57
view all 4 authors...
Source
12345678910